CD274 and cancer: Immune checkpoint inhibition (ICI) using monoclonal antibodies targeting the PD-1/PD-L1 axis are currently approved by the FDA for clinical use, with very good results in terms of improved progression-free survival (PFS) and overall survival (OS) in a variety of cancer types, including melanoma, lung, head and neck cancer and, invasive urothelial carcinoma.